ALPMY - Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage.
Until very recently, patients with acute myeloid leukemia ((AML)) had very few treatment options, and they were very likely to have a grim outcome. This was particularly true for less "fit" patients, including those who are older, since they may not be able to handle the best chemotherapy regimens that medicine had to offer.